RT Journal Article
SR Electronic
T1 Digital thErapy For Improved tiNnitus carE Study (DEFINE): Protocol for a Randomised Controlled Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.25.23296108
DO 10.1101/2023.09.25.23296108
A1 Smith, Matthew E
A1 Sharma, Dhiraj
A1 Rivero-Arias, Oliver
A1 Rand, Kim
A1 Barrack, Lucy
A1 Ogburn, Emma
A1 Young, Michael
A1 Field, Polly
A1 Multmeier, Jan
A1 Muzaffar, Jameel
YR 2023
UL http://medrxiv.org/content/early/2023/09/27/2023.09.25.23296108.abstract
AB Tinnitus is a common health condition, affecting approximately 15% of the UK population. The tinnitus treatment with the strongest evidence base is Cognitive Behavioural Therapy (CBT), with standard tinnitus therapy typically augmented with education, relaxation and other techniques. Availability of CBT and conventional tinnitus therapy more broadly is limited for tinnitus sufferers.The DEFINE trial aims to assess whether smartphone-delivered tinnitus therapy, the Oto app, is as effective as current standard care, one-to-one therapist-delivered tinnitus treatment for the treatment of tinnitus in adults. The trial is registered in the ISRCTN Registry: ISRCTN99577932.DEFINE is an open-label, non-inferiority, prospective, parallel design, randomised-controlled trial. Recruitment, interventions and assessments will be remote, enabling UK-wide participant involvement.198 participants aged 18 years or more will be recruited via social media advertisement or via primary care physicians. A screening process will identify those with tinnitus that impacts health-related quality of life, and following consent smartphone-based audiometry will be performed. Randomisation 1:1 to the Oto app or one-to-one therapist-led tinnitus therapy will be performed centrally by computer, matching groups for age, sex and hearing level. Following participant allocation, the Oto app will be provided for immediate use, or a one-to-one remote therapy appointment booked to occur within approximately 1 week, with up to 6 sessions delivered.Participant outcomes will be collected at 4,12, 26 and 52 weeks via questionnaire and phone call. The primary outcome is the change in Tinnitus Functional Index (TFI) total score measured at 26 weeks following allocation. Adverse events will be recorded. A health economic evaluation in the form of a cost-utility analysis will be performed using data from participant submitted EuroQol 5D-5L and Health Utilities Index Mark 3 scores and resource use data.Trial results will be made publicly available, including a plain English summary.Competing Interest StatementMS (Chief Investigator), OR-A, KR, LB, MY, EG and JMul have no competing interests OR-A and KR are employees at Maths in Health BV PF is an employee of Oxford Pharmagenesis Ltd DS is the Founder's Associate at Oto Health Ltd JMuz is Chief Scientific Officer for Oto Health Ltd DS and JM have financial interests in Oto Health LtdClinical TrialISRCTN99577932Funding StatementMS, JMuz, MY: INNOVATE UK Smart Grant 10062270Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Health Research Authority (West-Midlands committee), Ethics Reference: 23/WM/0146, IRAS ID: 328487.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.